他汀类药物预防脑卒中的高质量临床证据

被引:10
作者
赵美英
刘鸣
张世洪
方媛
李伟
机构
[1] 四川大学华西医院神经内科脑血管病临床研究中心
[2] 四川大学华西医院神经内科脑血管病临床研究中心 四川成都
关键词
他汀类药物; 脑卒中; 临床证据;
D O I
暂无
中图分类号
R743.3 [急性脑血管疾病(中风)];
学科分类号
1002 ;
摘要
目的探讨他汀类药物在脑卒中一级预防和二级预防中的效果及安全性。方法检索PubMed(1966—2006)、Cochrane图书馆(2006年第1期)、中国知识资源总库(1979—2006)及中文科技期刊数据库(1989—2006),获取并评价有关他汀类药物预防脑卒中的系统评价、Meta分析及随机对照试验。结果关于他汀类药物用于脑卒中的一级预防共检索到4篇Meta分析、8篇随机对照试验;关于脑卒中的二级预防共检索到1篇Cochrane系统评价和一项正在进行的随机对照试验。结论他汀类药物有望降低脑卒中的发生率,尤其对合并有冠心病、高血压、高血脂、糖尿病等脑血管病高危人群作用更为明显,在脑卒中的一级预防中有较为肯定的效果,且不增加出血性卒中和肿瘤的发生率;关于他汀类药物在脑卒中二级预防中的效果,目前高质量的临床证据尚不足,正在进行的卒中试验将为他汀类药物在脑卒中二级预防中的作用提供重要信息。
引用
收藏
页码:302 / 306
页数:5
相关论文
共 17 条
[1]  
Mortality by cause for eight regions of world:Global Burden of Disease Study. Murray CJ,Lopez AD. The Lancet . 1997
[2]  
Efficacy and safety of cholesterol-lowering treatment:prospective meta-analysis of data from90056participants in14randomised trials of statins. Cholesterol Treatment Trialists(CCT)Collaborators. The Lancet . 2005
[3]  
Statin in stroke pre-vention and carotid atherosclerosis:systematic review and up-to-date meta-analysis. Amarenco P,Labreuche J,Lavalleie P,et al. Stroke . 2004
[4]  
Interventions in the manage-ment of serum lipids for preventing stroke recurrence[Cochrane Review]. Manktelow B,Gillies C,Potter JF. Cochrane Database of Systematic Reviews . 2002
[5]  
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in20,536high risk individuals:a randomized placebo-controlled trial. Heart Protection Study Collaborative Group. The Lancet . 2002
[6]  
Differential effects of lipid-lowering therapies on stroke prevention:a meta-analysis of randomized trials. Corvol JC,Bouzamondo A,Sirol M,et al. Archives of Internal Medicine . 2003
[7]  
Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischemic Disease(LIPID)Study Group. The New England Journal of Medicine . 1998
[8]  
Reduction of stroke events with pravastatin:the PPP project. Byington RP,Davis BR,Plehn J F. Circulation . 2001
[9]  
Prosper Study Group-prospective study of pravastatin in the elderly at risk:pravastatin in elderly individuals at risk of vascular disease(PROSPER):a randomized controlled trial. Shepherd J,Blauw GJ,Murphy MB,et al. The Lancet . 2002
[10]  
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations. Sever PS,Dahlof B,Poulter NR,et al. The Lancet . 2003